Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Sector news Specialty & Advanced Pharmaceuticals
06/16International fund managers turn to financials, tech as trade worries rise
RE
06/15BAYER : Japan suspends sale of Canadian wheat after GMO wheat found in Alberta
RE
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15Indivior Shares Drop After U.S. Approves Suboxone Generics
DJ
06/15UK's Indivior to seek injunction after rival gets FDA approval for generics
RE
06/15NOVARTIS : Study Shows Jakavi Reduces Blood Clots, Risk of Death
DJ
06/15Roche's Gazyva Cancer Drug Outperforms MabThera
DJ
06/15NOVARTIS : Cohen Probe Is Extended to Lobbying -- WSJ
DJ
06/15SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/15NOVARTIS : Releases Phase 3 Data for Zessly, Erelzi Biosimilars
DJ
06/14ADRs End Mostly Lower; iQiyi, Unilever Trade Actively
DJ
06/14NOVARTIS : Prosecutors Investigating Michael Cohen for Possible Illegal Lobbying
DJ
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
RE
06/14GLAXOSMITHKLINE : Positive Results for ViiV Healthcare's HIV Studies
DJ
06/14SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/14Roche to Present Ocrevus Data Showing Delayed Wheelchair Need in MS Patients
DJ
06/14FDA Rejects Mylan's Asthma Generic Over Deficiencies -- Market Mover
DJ
06/13MERCK AND : Gets FDA Priority Review for Expanded Gardasil Age Range
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/13SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/12JOHNSON & JOHNSON : Accepts Platinum Equity's $2.1 Billion Offer for LifeScan Bu..
DJ
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials -- Update
DJ
06/12GSK says vaccine business president to leave by year-end
RE
06/12GLAXOSMITHKLINE : Vaccines President to Leave Company by Year-End
DJ
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials
DJ
06/12AstraZeneca, Eli Lilly to Stop Alzheimer's Treatment Trials
DJ
06/12SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/11Investors ready to resuscitate Johnson & Johnson's ailing stock
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
06/11Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
RE
06/11SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/11Roche's Venclexta Plus Rituxan Gets FDA Approval as Leukemia Treatment
DJ
06/08Brewers see future in high tech, weak beer, cannabis brews
RE
06/08ASTRAZENECA : Says EU Grants Marketing Authorization to Tagrisso
DJ
06/08Emirates starts London Stansted flights as rival airports near capacity
RE
06/08NOVO NORDISK A/S : shares fall after report of layoffs
RE
06/08SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/07EUROPE : European shares dip as luxury stocks fall; banks, oil up
RE
06/07PFIZER : wins appeal against UK fine for epilepsy drug price hike
RE
06/074D PHARMA : Plans Cancer-Treatment Trial With Merck & Co. Subsidiary
DJ
06/07SHIRE : Takeda Pharmaceutical Company Ltd Statement Regarding Press Article
DJ
06/07SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/07FORTIVE : Offers $2.7 Billion for J&J's Medical-Equipment Sterilization Business..
DJ
06/07FORTIVE : Correction to Fortive J&J Story
DJ
06/07CARL ICAHN : sources
RE
06/07J&J gets $2.7 billion offer for sterilization unit from Fortive
RE
06/06JOHNSON & JOHNSON : In Missouri, J&J faces biggest trial yet alleging talc cause..
RE
06/06FORTIVE : Offers $2.7 Billion for J&J's Medical-Equipment Sterilization Business
DJ
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 32 922 M
EBIT 2018 14 384 M
Net income 2018 10 789 M
Debt 2018 28 636 M
Yield 2018 3,60%
P/E ratio 2018 14,48
P/E ratio 2019 12,96
EV / Sales 2018 5,67x
EV / Sales 2019 5,25x
Capitalization 158 B